Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over

  • Highly specialised technologies guidance
  • HST33
  • Published: 
The topic was discussed at the Topic Selection Oversight Panel (TSOP) in March 2023. The panel concluded that the topic was suitable for a Technology Appraisal (TA) evaluation. The company have challenged the routing decision and the timelines for the evaluation are to be confirmed.